Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Anuradha Jayaram, Karolina Nowakowska, Joaquin Mateo, Sanjeev Kumar, Tatiana Hernandez, Ben Fulton, Daniel Nava Rodrigues, Ruth Riisnaes, Alexander Zukiwski, Alice Susannah Bexon, Stefan Proniuk, Charles Barranco, Diletta Bianchini, Zafeiris Zafeirou, Raquel Perez Lopez, Nina Tunariu, Simon Pacey, Robert J. Jones, Johann S. De Bono, Gerhardt Attard
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2889873077